内镜下组织胶注射对比组织胶联合BRTO或TIPSS预防胃静脉曲张出血:一项随机对照试验
研究纳入肝硬化合并胃底贲门静脉曲张急性出血、经内镜下氰基丙烯酸酯组织胶注射巩固止血后的患者,随机分为单纯内镜组与内镜联合放射介入组(经颈静脉肝内门体分流术或球囊闭塞逆行经静脉栓塞),各45例。1年胃静脉曲张再出血率介入组低于内镜组,再出血相关死亡率亦降低,但两组全因死亡率无差异。
要点
- 1年胃静脉曲张再出血率:内镜组24.4%,联合放射介入组2.2%,差异有统计学意义。
- 胃静脉曲张再出血相关死亡率内镜组17.8%高于联合放射介入组2.2%。
- 两组全因死亡率无差异;预防1例1年再出血需治疗人数为4.5。
核心结论
- 对胃静脉曲张出血患者,在组织胶注射止血后加用放射介入(经颈静脉肝内门体分流术或球囊闭塞逆行经静脉栓塞)作二级预防,可减少胃静脉曲张再出血及再出血相关死亡(CTRI/2021/02/031396)。
研究设计与样本
- 随机对照试验,连续纳入因胃底贲门静脉曲张急性出血的肝硬化患者,经内镜下氰基丙烯酸酯组织胶注射完成初始止血后随机分为2组,每组45例。
- 内镜干预组定期(1、3、6、12个月)重复内镜下组织胶注射;放射介入组行经颈静脉肝内门分门体分流术或球囊闭塞逆行经静脉栓塞,随后内镜监测。
主要发现
- 1年胃静脉曲张再出血率:内镜组11例(24.4%;95%CI 12.9%-39.5%)vs 放射介入组1例(2.2%;95%CI 0.1%-11.8%)(P=.004;绝对风险差22.2%;95%CI 8.4%-36.6%)。
- 胃静脉曲张再出血相关死亡:内镜组8例(17.8%;95%CI 8.0%-32.1%)vs 放射介入组1例(2.2%;95%CI 0.1%-11.8%)(P=.030;绝对风险差15.6;95%CI 2.9%-29.2%)。
- 全因死亡:内镜组12例(26.7%;95%CI 14.6%-41.9%)vs 放射介入组7例(15.6%;95%CI 6.5%-29.5%),两组无差异。
- 1年预防1例胃静脉曲张相关再出血的需治疗人数为4.5。
临床怎么用
- 原文结论为放射介入用于二级预防可减少胃静脉曲张再出血及再出血相关死亡,原文未据此给出进一步推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The study sought to compare the efficacy of endoscopic injection sclerotherapy with cyanoacrylate glue (EIS-CYA) vs EIS-CYA plus a radiologic intervention (RI) (either transjugular intrahepatic portosystemic shunt or balloon-occluded retrograde transvenous obliteration) for secondary prophylaxis in patients with liver cirrhosis who presented with acute variceal bleeding from cardiofundal varices. Primary outcome measure was gastric varix (GV) rebleed rates at 1 year. METHODS: Consecutive cirrhosis patients with acute variceal bleeding from cardiofundal varices were randomized into 2 arms (45 in each) after primary hemostasis by EIS-CYA. In the endoscopic intervention (EI) arm, EIS-CYA was repeated at regular intervals (1, 3, 6, and 12 months), while in the RI arm, patients underwent transjugular intrahepatic portosystemic shunt or balloon-occluded retrograde transvenous obliteration followed by endoscopic surveillance. RESULTS: GV rebleed rates at 1 year were higher in the EI arm compared with the RI arm: 11 (24.4%; 95% confidence interval [CI], 12.9%-39.5%) vs 1 (2.2%; 95% CI, 0.1%-11.8%) (P = .004; absolute risk difference: 22.2%; 95% CI, 8.4%-36.6%). GV rebleed-related mortality in the EI arm (8 [17.8%; 95% CI, 8.0%-32.1%]) was significantly higher than in the RI arm (1 [2.2%; 0.1%-11.8%]) (P = .030; absolute risk difference: 15.6; 95% CI, 2.9%-29.2%); however, there was no difference in all-cause mortality between the 2 groups (12 [26.7%; 95% CI, 14.6%-41.9%] vs 7 [15.6%; 95% CI, 6.5%-29.5%]). The number needed to treat to prevent 1 GV-related rebleed at 1 year was 4.5. CONCLUSIONS: RI for secondary prophylaxis reduces rebleeding from GV and GV rebleeding-related mortality in patients with GV hemorrhage. (CTRI/2021/02/031396).
引用
- Biswas S, Vaishnav M, Gamanagatti S, et al. Endoscopic Glue Injection vs Glue Plus BRTO or TIPSS for Preventing Gastric Variceal Bleeding: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2024. PMID: 38969074. doi:10.1016/j.cgh.2024.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。